English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduResearchers at Children’s Hospital of Philadelphia (CHOP) and the Children’s Oncology Group (COG) announced the results of a Phase 3 study that demonstrated adding the bi-specific T-cell engager, blinatumomab, to chemotherapy for newly diagnosed National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) pediatric patients significantly improves survival outcomes. The results were published today in the New England Journal of Medicine and will be presented during the plenary session at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego on December 8.
Tag: ASH 2024 Annual Meeting
MD Anderson Research Highlights: ASH 2024 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. This special edition features upcoming oral presentations by MD Anderson researchers at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, providing new insights and advances in hematological malignancies and diseases. All ASH content from MD Anderson can be found at MDAnderson.org/ASH.
Sylvester Cancer Tip Sheet: Researchers Present Posters at the 66th ASH Annual Meeting & Exposition
Hematology researchers from Sylvester Comprehensive Cancer Center and the Miller School of Medicine at the University of Miami are authors or co-authors on more than 70 posters to be presented at the Annual Meeting & Exposition of the American Society of Hematology in San Diego, Dec. 7-10. Links to each abstract are included in this tip sheet.